• 1. Novel total syntheses of oxoaporphine alkaloids enabled by mild Cu-catalyzed tandem oxidation/aromatization of 1-Bn-DHIQs
  Bo Zheng,Hui-Ya Qu,Tian-Zhuo Meng,Xia Lu,Jie Zheng,Yun-Gang He,Qi-Qi Fan,Xiao-Xin Shi RSC Adv. 2018 8 28997
• 2. Studies on the syntheses of heterocyclic compounds. Part CCCLXXXV. Pschorr reactions of 1-(2-aminobenzyl)- and 1-(2-aminophenethyl)-1,2,3,4-tetrahydroisoquinolines (total synthesis of thalicsimidine)
  T. Kametani,K. Takahashi,T. Sugahara,M. Koizumi,K. Fukumoto J. Chem. Soc. C 1971 1032

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Phenethylamines

2-(2,3,4-trimethoxyphenyl)ethan-1-amine: A Promising Compound in Pharmaceutical Research

2-(2,3,4-trimethoxyphenyl)ethan-1-amine, with the chemical identifier CAS No. 3937-16-4, is a multifunctional organic compound that has garnered significant attention in the field of pharmaceutical research. This molecule, characterized by its unique structural framework, combines aromatic and aliphatic moieties, which may confer distinct biological activities. Recent advancements in medicinal chemistry have highlighted the potential of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine as a scaffold for the development of novel therapeutics targeting various pathological conditions. The integration of synthetic strategies with pharmacological profiling has enabled researchers to explore its versatility in drug discovery pipelines.

The molecular architecture of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine is defined by the presence of a trimethoxyphenyl group attached to an ethylamine backbone. The trimethoxyphenyl substituent introduces electron-donating functionalities, which can influence the compound's reactivity and biological interactions. These structural features are critical for modulating its pharmacokinetic properties, such, as solubility, bioavailability, and metabolic stability. Recent studies have demonstrated that the methoxy groups on the aromatic ring may enhance the compound's ability to interact with specific protein targets, thereby improving its therapeutic potential.

Recent research on 2-(2,3,4-trimethoxyphenyl)ethan-1-amine has focused on its potential applications in neuropharmacology and anti-inflammatory therapies. A 2023 study published in Journal of Medicinal Chemistry reported that derivatives of this compound exhibit selective agonist activity at the adenosine A2A receptor, a target implicated in neurodegenerative diseases. The study highlighted the compound's ability to modulate intracellular signaling pathways, suggesting its potential as a therapeutic agent for conditions such as Parkinson's disease. These findings underscore the importance of structural optimization in enhancing the compound's efficacy and selectivity.

Another area of interest is the role of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine in anti-inflammatory applications. A 2024 preclinical study in Pharmacological Research demonstrated that the compound exhibits potent anti-inflammatory effects by inhibiting the activation of nuclear factor-kappa B (NF-κB), a key regulator of inflammatory responses. The study also noted the compound's ability to reduce oxidative stress, which is a common feature in chronic inflammatory diseases. These properties make 2-(2,3,4-trimethoxyphenyl)ethan-1-amine a promising candidate for the development of novel anti-inflammatory drugs.

The synthesis of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine has been optimized using modern organic methodologies to ensure high yields and purity. A 2023 paper in Organic Letters described a scalable synthetic route involving the coupling of 2,3,4-trimethoxybenzene with ethylamine via a nucleophilic substitution reaction. The use of catalytic systems and green chemistry principles in this process aligns with current industry standards for sustainable drug development. The resulting compound was further purified using chromatographic techniques, ensuring its suitability for pharmaceutical applications.

Pharmacokinetic studies of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine have revealed its favorable absorption, distribution, metabolism, and excretion (ADME) profile. A 2024 study in Drug Metabolism and Disposition reported that the compound exhibits rapid oral absorption in animal models, with a half-life that is suitable for once-daily dosing regimens. The metabolic stability of the compound was further enhanced through the introduction of methoxy groups, which may reduce the risk of enzymatic degradation in vivo. These properties are critical for the development of long-acting formulations.

Recent advances in computational modeling have provided insights into the molecular interactions of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine with biological targets. A 2023 study in Computational and Structural Chemistry used molecular docking simulations to predict the compound's binding affinity for the adenosine A2A receptor. The results indicated that the trimethoxyphenyl group plays a crucial role in stabilizing the receptor-ligand complex, which may explain the compound's selectivity for this target. These findings have guided the design of more potent analogs with improved therapeutic indices.

The potential of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine as a lead compound for drug development has also been explored in the context of cancer therapy. A 2024 study in Cancer Research investigated its ability to inhibit the proliferation of cancer cells by targeting specific signaling pathways. The compound was shown to induce apoptosis in tumor cells while sparing normal cells, suggesting its potential as a chemotherapeutic agent. Further studies are needed to elucidate the mechanisms of its cytotoxic effects and to optimize its therapeutic profile.

Challenges in the development of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine as a therapeutic agent include the need for further preclinical and clinical validation. While preclinical studies have demonstrated its biological activity, larger-scale trials are required to assess its safety and efficacy in human subjects. Additionally, the compound's potential for drug-drug interactions must be carefully evaluated, particularly in patients with comorbid conditions. These considerations highlight the importance of a multidisciplinary approach in the development of novel therapeutics.

Despite these challenges, the unique properties of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine position it as a valuable candidate for the development of innovative treatments. Ongoing research efforts are focused on refining its chemical structure to enhance its therapeutic potential while minimizing adverse effects. The integration of advanced analytical techniques and computational tools is expected to accelerate the discovery of new compounds with optimized biological activities. As the field of medicinal chemistry continues to evolve, the role of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine in drug discovery is likely to expand, offering new opportunities for the treatment of complex diseases.

In conclusion, the study of 2-(2,3,4-trimethoxyphenyl)ethan-1-amine represents a significant advancement in the field of pharmaceutical research. Its structural versatility, combined with its potential biological activities, makes it a promising candidate for the development of novel therapeutics. Continued research efforts are essential to fully realize its therapeutic potential and to address the challenges associated with its clinical application. As the scientific community explores new frontiers in drug discovery, the role of compounds like 2-(2,3,4-trimethoxyphenyl)ethan-1-amine is likely to become increasingly important in the quest for effective treatments for a wide range of diseases.

• 1083-09-6(Benzeneethanamine,2,4,5-trimethoxy-a-methyl-)
• 3166-74-3(2,5-Dimethoxyphenethylamine hydrochloride)
• 53663-28-8((2,3-dimethoxyphenyl)methyl(methyl)amine)
• 3213-29-4(2,3-DIMETHOXYPHENETHYLAMINE)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)